Luxembourg · Pre-Seed–Series B · 13 people tracked
Find your way into Droia Ventures
1,765 people in our graph share verified history with the Droia Ventures team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Droia invests globally and exclusively in therapeutics companies focused on oncology and genetic disease. It targets young drug development firms whose technology platforms or scientific insights address previously unsolvable clinical problems and translate innovation into clinical breakthroughs. As hands-on investors and entrepreneurs with an in-house team of drug development experts, Droia supports companies from creation through clinical proof of concept, often taking interim roles and building companies from the ground up. Through Droia Labs, its scientific arm, the firm validates novel ideas and provides state-of-the-art facilities. Success is measured in patient benefit relative to the severity of unmet medical need and improvement over standard of care.
Source: firm website, verified Sep 20, 2026.
Team · 13 people
from curated & public directories
What they invest in
from 28 of 34 portfolio companiesBiotech ×26Healthtech ×17Deep Tech ×9Medical Devices ×9AI & Machine Learning ×7Digital Health ×3Longevity ×2Advanced Manufacturing ×1
HQs:United States×14Belgium×2Switzerland×1Netherlands×1
Who they back
founder profiles across 13 portfolio companiesFounding team size:solo founder×32 founders×83 founders×14+ founders×1
Where their founders studiedfrom 15 founders with education data
Imperial College London ×2Massachusetts Institute of Technology ×2
What their founders studiedfrom 14 founders with field-of-study data
Life Sciences ×8Chemistry ×4Medicine ×2
Investments · 34 tracked
founders shown can be your intro pathBy year:2025 · 42024 · 32022 · 12021 · 52019 · 114 dated
Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.
BiotechHealthtechMedical DevicesCambridge, US
Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)
Co-investorsAdvent Life SciencesChiesi VenturesForesite CapitalJazzya InvestmentsMedicxiMyelin VC+4 more
Hyku Biosciences develops small molecule therapeutics with novel mechanisms of action designed to covalently bind non-cysteine amino acids and inactivate disease-driving proteins.
BiotechDeep TechMedical DevicesBurlington, US
KLEEM CHAUDHARY(Executive Officer, Director, Promoter)inKu-Lung (Ken) Hsu, PhD(Endowed Associate Professor of Chemistry)Kleem Chaudhary, PhD(President & CEO)
BoardJOHN GUSTOFSON(Director)LAURA BRASS(Director)inLAURA TADVALKAR(Director)in
Board seatJanwillem NaesensMatthias Van Woensel· per SEC Form D
Co-investorsEisai Innovation, Inc.Novartis Venture FundRA Capital
Judo Bio develops oligonucleotide medicines, including ligand-siRNA conjugate drugs, delivered to the kidney for systemic and renal diseases using its STRIKE (Selectively Targeting RNA Into KidnEy) platform.
BiotechHealthtechCambridge, US
Andrew Fraley(Co-founder)inAlfica SehgalinOMMER CHOHAN(Executive Officer)inJAMES JEFFREY GOATER(Executive Officer, Director)Simon Read(CEO)inWilliam Ho
Co-investorsAtlas VentureDigitalis VenturesThe Column GroupYK Bioventures
Montis Biosciences develops anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome and a second CD93 program in lung squamous cell carcinoma.
BiotechHealthtechLeuven, BE
Federico Grossi(Clinical Advisor & Acting CMO)
Co-investorsPfizer VenturesVIBPfizer Venture InvestmentsPolaris Partners
Vico Therapeutics develops targeted genetic medicines for neurological disorders, with a focus on antisense oligonucleotide therapies designed to address the underlying genetic causes of diseases like Huntington's disease and spinocerebellar ataxias.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Luc Dochez(Chair and Founder)inJosh Mandel-Brehm(Co-Founder)in
Co-investorsKurma PartnersPureos BioventuresEQT Life SciencesSeroba Life SciencesEurazeoIdinvest Partners+1 more
Montis Biosciences is a biotechnology company developing anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome.
BiotechHealthtechLeuven, BE
Federico Grossi(Clinical Advisor & Acting CMO)
Co-investorsPfizer VenturesVIBPfizer Venture Investments
Volastra Therapeutics is a drug discovery and development company working on novel cancer therapies.
BiotechHealthtechNew York, US
Samuel Bakhoum(Co-Founder & Chief Scientific Officer)inLewis Cantley(Founder and Chair of Scientific Advisory Committee)Olivier Elemento(Founder and Scientific Advisor)David P. Southwell(Chief Executive Officer)in
BoardRobert Mittendorff(Director)inJill Goldstein(Director)in
Co-investorsARCH Venture PartnersB Capital GroupB4 CapitalVida VenturesPolaris Partners
.jpeg){kind=logo}
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
BiotechDeep TechMedical DevicesEindhoven, US
Christian Ottmann(Executive Officer)inJosh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)
Board seatJanwillem Naesens· per SEC Form D
Co-investorsMission BiocapitalMRL Ventures FundNextech InvestInkefRA Capital
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Co-founder)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)inShafique Virani(Executive Officer)inJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in
Board seatLuc Dochez· per SEC Form D
Co-investorsMC Healthcare VenturesMission BiocapitalMitsui Global InvestmentSanofi VenturesSV Health InvestorsAmgen Ventures+7 more
Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.
BiotechHealthtechLongevity
Co-investorsAtlas VentureEcoR1 CapitalGV (Google Ventures)The Column GroupJJDCJohnson & Johnson Innovation – JJDC+1 more
Actio is a precision medicine company developing therapeutics by leveraging genetic insights to treat rare diseases and common conditions at their molecular root.
AI & Machine LearningBiotech
Co-investorsCanaan PartnersDeerfield Management Company
Alesta Therapeutics develops therapies for rare diseases, with research focused on genetic diseases and oncology.
BiotechHealthtech
Ilan Ganot(CEO)inBenit Maru(CMO)Matthias Van Woensel(CSO)in
Co-investorsFrazier Life SciencesNovartis Venture FundFrazier Healthcare PartnersMPM BioImpactRTW Investments L.P.Thuja Capital
Arcus Biosciences develops combination cancer therapies, producing small molecules and antibodies designed to be combined and advanced from Phase 1 studies through commercialization.
Biotech
Juan Jaen(Founder)in
Co-investorsAisling CapitalDecheng CapitalEcoR1 CapitalForesite CapitalSLVCSofinnova Ventures+2 more
Cristal Therapeutics develops therapeutics in the life sciences sector.
BiotechDeep TechDigital HealthMedical DevicesUtrecht, NL
Dr. Cristianne Rijcken(Chief Scientific Officer and Founder)Dr. Joost Holthuis(Co-founder and former CEO)
Co-investorsBioGeneration VenturesChemelot VenturesThuja CapitalBOM
Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters.
BiotechHealthtechCambridge, US
Kevin Mills(Executive Officer, Director)inRonald Goldstein(Executive Officer)inDonald Corcoran(Executive Officer, Director)inMarkus Renschler(Director)in
BoardTimothy Romberger(Director)Barry Mills(Director)
Co-investorsLightstone VenturesOUP (Osage University Partners)Ally Bridge GroupDe Novo VenturesJanus Henderson InvestorsNovo Holdings+3 more
Frontier is a drug discovery company developing small-molecule covalent drugs aimed at previously undruggable protein targets across the proteome.
AI & Machine LearningBiotechSouth San Francisco, US
Chris Varma, Ph.D.(Executive Officer, Director)Chris Varma(Co-founder, Chairman and CEO)inJim Winkler(Executive Officer)Johannes Hermann, Ph.D.(Executive Officer)Kevin Webster(Executive Officer)inGregory Chow(Executive Officer)
Co-investorsBerkeley CatalystDCVC (Data Collective)MPM BioImpactRA CapitalDCVC BioDeerfield Management Company
Highlight Therapeutics is a biotech company developing therapeutic treatments.
BiotechHealthtech
Marisol Quintero(Chief Operating Officer (former CEO 2013-2025))in
Co-investorsBuenavista Equity PartnersColumbus Venture Partners
Hillstar Bio develops precision immunotherapies for autoimmune diseases, using antibody engineering to selectively deplete pathogenic immune cells while sparing healthy ones.
BiotechHealthtech
Co-investorsFrazier Life SciencesLifeArc Ventures
OLG Machinery, founded in 2008, trades new and certified used industrial spare parts and machinery, serving U.S. companies operating across North and South America with a focus on Mexico.
Advanced ManufacturingB2B MarketplacesLogistics & Supply Chain
Co-investorsOxford Investment Opportunity Network (OION)Ally Bridge GroupAltium CapitalAmgen VenturesFrazier Healthcare PartnersNovo Holdings+2 more
Hummingbird Bioscience is a precision biotherapeutics company developing a pipeline of novel targeted therapies for cancer, using proprietary drug discovery technologies and platforms.
AI & Machine LearningBiotechDeep TechHealthtech
Piers Ingram(Chief Executive Officer, Co-Founder, Executive Director)inJerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)inKonrad Paszkiewicz(Chief Technology Officer)inKwek Kon Yew(Chief Medical Officer)Dipti Thakkar(Chief Operating Officer)in
Co-investorsAltium CapitalClavystBioDecheng CapitalFrazier Life SciencesKiwoom InvestmentMuirwoods Ventures+5 more
Mahzi develops therapies for patients with under-diagnosed and under-served rare genetic neurodevelopmental disorders, working with patient and family groups, academic researchers, and industry partners.
BiotechHealthtechSouth San Francisco, US
Yael Weiss(Executive Officer, Director)in
BoardCamille Samuels(Director)inMarten Steen(Director)inShalini Sharp(Director)inStephen Farr(Director)
Co-investorsHealthCapMitsui Global InvestmentVenrockVenrock Associates
Muna Therapeutics is a biotechnology company developing therapeutics, with a focus on drug discovery involving medicinal chemistry.
BiotechDeep TechHealthtechLongevity
Rita Balice-Gordon(Founder)inJoachim Vilstrup(Head of Protein Chemistry and Structural Biology; scientific co-founder)inMichel Detheux(Chief Executive Officer & Board Director)inAnders Hinsby(Chief Operating Officer)inNiels Plath(Chief Scientific Officer)inJakob Busch-Petersen(Chief Development Officer)in
Co-investorsSanofi VenturesSofinnova PartnersV-Bio Ventures
Developing highly selective MET kinase inhibitors (Beerse, Belgium).
Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSan Diego, US
Brent J. Warner(Executive Officer, Director)inXIN JIANG(President & CEO)inHANK MICHAEL PETRASSI(Executive Officer)JEFFERY KELLY(Director)
BoardTIM LOHOFF(Director)Edward Hurwitz(Director)
Co-investorsNovartis Venture FundDigitalis VenturesForbionLightspeed Venture PartnersMPM BioImpactVida Ventures+1 more
Roche develops diagnostics and pharmaceutical medicines to address major healthcare challenges and improve patient outcomes across prevention, treatment, and cure.
BiotechDigital HealthHealthtechMedical Devices
Unnatural Products is a drug discovery platform company that develops synthetic macrocycles to target previously undruggable disease targets.
AI & Machine LearningBiotechDeep TechMedical DevicesSanta Cruz, US
Cameron Pye(Co-Founder & CEO)inJoshua Schwochert(Co-Founder & CSO)in
BoardVasudev Bailey(Director)in
Co-investorsAbstract VenturesArtis VenturesAsset Management CompanyBetter Ventures Central LlcBlue Bear VenturesFirst Spark Ventures, Llc+6 more
.png)
Vaderis develops a first-of-its-kind oral therapy for hereditary hemorrhagic telangiectasia (HHT), a rare vascular disease with no existing approved treatments.
BiotechHealthtechMedical Devices
Co-investorsMedicxiEQT Life SciencesGoldman Sachs
VICO provides AI-generated forecasts and event risk ratings that track and triangulate analyst views into continuous time series data.
AI & Machine LearningData & InfrastructureFintech
Co-investorsAIN VenturesMultiball CapitalEQT Life SciencesEurazeoKurma PartnersPureos Bioventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Summation BioHillstar BioHykuJudoSmall MoleculesVaderis
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 1
1 IPOsAura BiosciencesNASDAQ: AURA
Portfolio news
latest coverage across their companies
Vaderis Therapeutics · fiercebiotech.com · Sep 9, 2026
Hummingbird · daysofobservance.com · Sep 4, 2026
Arcus Biosciences · pluang.com · Aug 19, 2026
Alesta · axios.com · Aug 18, 2026
Aura Biosciences · tickerreport.com · Aug 18, 2026
Mahzi Therapeutics · forbes.com · Jul 13, 2026
Protego Biopharma · finsmes.com · Apr 23, 2026
Frequently asked questions
- How many investments has Droia Ventures made?
- Droia Ventures has 34 tracked investments, 1 of which have exited, including 4 dated in the last 24 months.
- What stage does Droia Ventures invest at?
- Droia Ventures invests at the Pre-Seed, Seed, Series A, Series B stages.
- What is Droia Ventures's typical check size?
- Droia Ventures typically writes checks of $540K.
- What sectors does Droia Ventures focus on?
- Droia Ventures focuses on Biotech, Healthtech, Medical Devices.
- Where is Droia Ventures located?
- Droia Ventures is headquartered in Luxembourg, LU.
- Does Droia Ventures lead rounds?
- Droia Ventures typically participates in rounds rather than leading them.
- Who does Droia Ventures co-invest with?
- Droia Ventures most often shares deals with Frazier Life Sciences, Novartis Venture Fund, Foresite Capital, among 63 tracked co-investors.
Images
Similar investors
Wing is a venture capital firm that invests in early-stage technology companies, with a portfolio focused on AI infrastructure, frontier models, real-world AI, and healthcare.
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.
Forbion is a global venture capital firm focused on advancing biotech innovations and sustainable solutions aimed at improving human and planetary health.
Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.